Denali Therapeutics (DNLI) Equity Average (2018 - 2026)

Denali Therapeutics (DNLI) has 9 years of Equity Average data on file, last reported at $969.9 million in Q1 2026.

• Quarterly Equity Average fell 17.54% year-over-year to $969.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $969.9 million (down 17.54% YoY) and the FY2025 annual result came in at $1.1 billion, down 0.76% from the prior year.
• Equity Average was little changed at $969.9 million in Q1 2026 per DNLI's latest filing, from $970.0 million in the prior quarter.
• Across five years, Equity Average topped out at $1.4 billion in Q2 2024 and bottomed at $847.9 million in Q3 2022.
• The 5-year median for Equity Average is $1.1 billion (2023), against an average of $1.1 billion.
• The widest annual swing landed in 2023, when Equity Average surged 35.94%; it then declined 27.81% in 2025.
• Tracing DNLI's Equity Average over 5 years: stood at $926.9 million in 2022, then climbed by 15.94% to $1.1 billion in 2023, then climbed by 18.56% to $1.3 billion in 2024, then declined by 23.87% to $970.0 million in 2025, then retreated by 0.01% to $969.9 million in 2026.
• Per Business Quant, the three latest DNLI Equity Average figures stand at $969.9 million (Q1 2026), $970.0 million (Q4 2025), and $976.6 million (Q3 2025).

Peer Comparison